Price$227.31+1.69 (+0.75%)
01:30 PM07:45 PM
News · 26 weeks126+125%
2025-11-022026-04-26
Mix8990d
- Insider41(46%)
- Other37(42%)
- SEC Filings7(8%)
- Earnings2(2%)
- M&A1(1%)
- Analyst1(1%)
Latest news
25 items- SECJohnson & Johnson filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- INSIDERSEC Form 4 filed by Director Woods Eugene A.4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director West Nadja4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Weinberger Mark A4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Pinto Daniel E4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Morikis John G4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcclellan Mark B.4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Joly Hubert4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson Paula A4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Hewson Marillyn A4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Doudna Jennifer A4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Beckerle Mary C4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- PRJohnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions ConferenceJohnson & Johnson (NYSE:JNJ) will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260427510768/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.c
- PRFDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemiaIMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemiaSPRING HOUSE, Pa., April 27, 202
- SECSEC Form 10-Q filed by Johnson & Johnson10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
- PRIMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 studyEPIC, the first head-to-head study of IMAAVY versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participantsHORSHAM, Pa., April 22, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population o
- PRJohnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260421719308/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- PRJohnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiology A total of 17 abstracts will be presented, including new clinical data for the VARIPULSE Platform Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting, including new evidence in pulsed field ablation (PFA), and innovations in cardiac mapping and imaging. At HRS 2026, the company will launch the CARTOSOUND SONATA Module, leveraging artificial intelligence with the CARTO System to automatically transform intracardiac echoc
- PRThe Infrastructure Play Hiding in Plain Sight Across Cardiac CareVANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra
- PRJohnson & Johnson to Participate in the Bank of America 2026 Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12th, 2026. Management will participate in a Fireside Chat at 2:20 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260415624527/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- SECJohnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRJohnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr
- PRJohnson & Johnson reports Q1 2026 results, raises 2026 outlook2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIP
- PRJohnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of VisionRobust clinical data, spans two major studies across U.S., Europe and Asia Pacific Data reveals TECNIS PureSee IOL achieved exceptional distance and intermediate vision, low bothersome visual symptoms, high tolerance to post-op refractive errors High patient satisfaction results with TECNIS PureSee IOL Johnson & Johnson (NYSE:JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 10-13 in Washington, DC. TECNIS PureSee IOL is J&J's next-generation Extended Depth of Focus (EDOF) IOL, which demonstrates excelle
- PRRobotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term ValueAUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is entering a period of structural transformation as regulators impose increasingly stringent expectations around contamination control, data integrity and operational traceability. The European Union's updated GMP Annex 1 guidance places strong emphasis on minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to evaluate and mitigate risks across personnel, processes and environments. It also encourages the use of barrier systems and automation technologies, reflecting the widely accepted understanding that human oper
JNJ FAQ
7 questionsWhat does Johnson & Johnson do?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL...Where does JNJ stock trade?
Johnson & Johnson (JNJ) is listed on NYSE.What sector and industry is JNJ in?
Johnson & Johnson operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does JNJ pay a dividend?
Yes. JNJ's next ex-dividend date is 2026-05-26 with a declared cash dividend of $1.34 per share, payable 2026-06-09.What are analysts saying about JNJ?
Johnson & Johnson has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-04-08.What companies are similar to JNJ?
Notable peers in the same industry include AZN (AstraZeneca PLC), NVS (Novartis AG), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), UL (Unilever PLC). Compare JNJ side-by-side with any of them on Quantisnow.How can I track JNJ on Quantisnow?
Quantisnow aggregates Johnson & Johnson's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JNJ to receive live email and push alerts on every new disclosure.